{"success":true,"data":{"pressRelease":{"id":"164685","rtpr_id":"nGNXbzpFNJ-20261008","ticker":"BMGL","exchange":"NASDAQ","all_tickers":["BMGL"],"title":"Basel Medical Group Ltd (BMGL) Prices Registered Direct Offering","author":"Globe Newswire","published_at":"2026-10-08T17:17:00.099Z","article_body":"Singapore, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq:\nBMGL) (the “Company”) today entered into a placement agency agreement with\nCathay Securities, Inc., as the placement agent (the “Placement Agent”),\nas well as a securities purchase agreement with certain purchasers, pursuant\nto which the Company will issue and sell 6,000,000 units (the “Units”), at\na public offering price of US$1.33 per Unit, each consisting of one ordinary\nshare with no par value (each an “Ordinary Share” and collectively the\n“Ordinary Shares”) or one Pre-Funded Warrant (defined below) of the\nCompany, and one warrant (“Common Warrant”), each to purchase one Ordinary\nShare.\n\nThe Ordinary Shares are listed on the Nasdaq Capital Market under the symbol\n“BMGL”. The Common Warrants and Pre-Funded Warrants will not be listed or\nquoted on any exchange. The total gross proceeds to the Company from the\noffering, before deducting commissions and offering expenses, will be US$7.98\nmillion. The Company estimates that its net proceeds from this offering will\nbe approximately US$7.28 million. The Ordinary Shares issued and to be issued\nupon warrant exercise and pursuant to this offering are registered pursuant to\nthe Company’s effective registration statement on Form F-1 (File No.\n333-298988) (the “Registration Statement”) and will be freely tradeable\nwithout restriction following the closing of this offering.\n\nEach Common Warrant is exercisable immediately on the date of issuance at an\nexercise price per share equal to 110% of the public offering price of each\nUnit sold in this offering and will expire five years from the date of\nissuance. A holder of Common Warrants may, at any time following the closing\nof this offering within the exercise period and in its sole discretion,\nexercise its Common Warrants in whole or in part by means of a zero cash\nexercise price option, in which the holder will receive the number of Ordinary\nShares that would be issuable upon a cash exercise of the Common Warrant,\nwithout payment of additional consideration, or a total of 6,000,000\nadditional Ordinary Shares in the aggregate. As a result, we will likely not\nreceive any additional funds and do not expect to receive any additional funds\nupon the exercise of the Common Warrants. If all of the 6,000,000 Common\nWarrants offered to investors in this offering are exercised on a zero cash\nbasis, an aggregate of 6,000,000 Ordinary Shares would be issued upon such\nzero cash exercise without payment to us of any additional cash.\n\nEach purchaser who purchased Units that would otherwise result in the\npurchaser’s beneficial ownership exceeding 4.99% (or, at the election of the\nholder, such limit may be increased to up to 9.99%) of our outstanding\nOrdinary Shares, were offered the opportunity to purchase Units consisting of\none pre-funded warrant (in lieu of one Ordinary Share, each a “Pre-Funded\nWarrant”) and one Common Warrant. Subject to limited exceptions, a holder of\nPre-Funded Warrants will not have the right to exercise any portion of its\nPre-Funded Warrants if the holder, together with its affiliates, would\nbeneficially own in excess of 4.99% (or, at the election of the holder, such\nlimit may be increased to up to 9.99%) of the number of Ordinary Shares\noutstanding immediately after giving effect to such exercise. Each Pre-Funded\nWarrant will be exercisable for one Ordinary Share. The purchase price of each\nUnit that includes a Pre-Funded Warrant is the final Unit offer price less\nUS$0.01, and the remaining exercise price of each Pre-Funded Warrant will\nequal US$0.01 per share. The Pre-Funded Warrants will be immediately\nexercisable (subject to the beneficial ownership cap) and may be exercised at\nany time until all of the Pre-Funded Warrants are exercised in full.\n\nImmediately prior to this offering, the Company had a total of 1,582,111\nOrdinary Shares issued and outstanding. Immediately upon the completion of the\noffering, the Company will have a total of 7,582,111 Ordinary Shares issued\nand outstanding and a total of 6,000,000 Common Warrants issued and\noutstanding.\n\nThe Company and all of our executive officers, directors and certain\nshareholders beneficially owning 5.0% or more of our ordinary shares prior to\nthis offering have entered into lock-up agreements in connection with the\noffering. Under these agreements, the Company and each of these persons may\nnot, without the prior written approval of the Placement Agent, offer, sell,\ncontract to sell or otherwise dispose of or hedge Ordinary Shares or\nsecurities convertible into or exchangeable for Ordinary Shares, subject to\ncertain exceptions. The restrictions contained in these agreements will be in\neffect for a period of 180 days for the Company and 180 days for the executive\nofficers, directors and such shareholders, after the date of the closing of\nthis offering. The Company has agreed that, for a period of 180 days following\nthe closing date of this offering, it will not, without the prior written\nconsent of the Placement Agent, directly or indirectly issue, offer, sell,\ncontract to sell, grant any option to purchase, or otherwise dispose of any\nOrdinary Shares or any securities convertible into, exercisable for, or\nexchangeable for Ordinary Shares, other than a prospectus filed with the\nCommission pursuant to Rule 424(b) in connection with this offering,\nsupplements or amendments to registration statements or supplements previously\nfiled. The Company has also agreed that, during the same 180 days, it will not\nenter into or consummate any financing or capital-raising transaction,\nincluding any equity line of credit, equity financing, convertible bond,\nconvertible note, other equity-linked financing, or variable rate transaction,\nwithout the prior written consent of the Placement Agent.\n\nCathay Securities, Inc. is acting as exclusive placement agent in connection\nwith this offering. Sichenzia Ross Ference Carmel LLP is acting as counsel to\nthe Company regarding U.S. securities law matters. Hunter Taubman Fischer & Li\nLLC is acting as U.S. securities counsel for the placement agent.\n\nThe securities described above are being offered pursuant to the Registration\nStatement, which was declared effective by the U.S. Securities and Exchange\nCommission (the “SEC”) on September 29, 2026. The offering is being made\nonly by means of a prospectus which is a part of the Registration Statement. A\npreliminary prospectus relating to the offering has been filed with the SEC.\nCopies of the final prospectus relating to the offering, when available, may\nbe obtained from Cathay Securities, Inc., 40 Wall Street, Suite 3600, New\nYork, NY 10005, Attention: Shell Li, or by calling +1 855-939-3888, by email\nrequest to service@cathaysecurities.com.\n\nBefore you invest, you should read the prospectus and other documents the\nCompany has filed or will file with the SEC for more complete information\nabout the Company and the offering. This press release shall not constitute an\noffer to sell, or the solicitation of an offer to buy any of the Company’s\nsecurities, nor shall such securities be offered or sold in the United States\nabsent registration or an applicable exemption from registration, nor shall\nthere be any offer, solicitation or sale of any of the Company’s securities\nin any state or jurisdiction in which such offers, solicitations or sales\nwould be unlawful prior to registration or qualification under the securities\nlaws of such state or jurisdiction. Any offers, solicitations, or offers to\nbuy, or any sales of securities will be made in accordance with the\nregistration requirements of the Securities Act of 1933, as amended.\n\nAbout Basel Medical Group Ltd\n\nBasel Medical is a Singapore-based provider of orthopedic and trauma services,\nsports medicine, orthopedic procedures and surgery, as well as neurosurgical\ntreatments, executive health screening services, occupational medicine,\nrehabilitation, mental and women’s health and general medical practices. Our\noperations are based in Singapore, with our clinics being located at Suntec\nCity Mall, Macpherson Road, Toa Payoh, Margaret Drive, Tampines, Gateway East\nand Gleneagles Medical Centre. Over the last 20 years, our group has forged\nstrong and lasting relationships with a wide corporation clientele,\nparticularly those in the construction, marine and oil & gas industries, which\nunderpin our robust business model. As an medical service provider in\nSingapore with a track record of over 20 years, we are well-positioned to ride\nthe wave of growth opportunities in the private healthcare industry in\nSingapore and across Southeast Asia driven by ageing populations, rising\nincome levels, increasing private insurance coverage, increasing expenditure\non healthcare, growing sports participation rate and Singapore’s position as\na premium destination for healthcare services in Asia. Our management and\nmedical practitioner team comprises a roster of orthopedic and neurosurgery\nspecialists, general practitioners, corporate finance and healthcare\npartnership specialists. Basel Medical Group Ltd serves as the holding company\nof our group and we conduct our operations through our operating subsidiaries\nbased in Singapore. For more information, please visit the Company’s\nwebsite: www.baselmedical.com.\n\nForward-Looking Statements\n\nCertain statements in this announcement are forward-looking statements, which\ninvolve known and unknown risks and uncertainties and are based on the\nCompany’s current expectations and projections about future events that may\naffect its financial condition, results of operations, business strategy and\nfinancial needs. Investors can find many (but not all) of these statements by\nthe use of words such as “aim”, “anticipate”, “believe”,\n“estimate”, “expect”, “going forward”, “intend”, “may”,\n“plan”, “potential”, “predict”, “propose”, “seek”,\n“should”, “will”, “would” or other similar expressions in this\npress release. The Company undertakes no obligation to update or revise\npublicly any forward-looking statements to reflect subsequent occurring events\nor circumstances, or changes in its expectations, except as may be required by\nlaw. Although the Company believes that the expectations expressed in these\nforward-looking statements are reasonable, it cannot assure you that such\nexpectations will turn out to be correct, and the Company cautions investors\nthat actual results may differ materially from the anticipated results and\nencourages investors to review other factors that may affect its future\nresults in the Company’s filings with the SEC.\n\nMedia Contact:\n\nBasel Medical Group Ltd\nPhone: +65 6291 9188\nE-mail: contact@baselmedical.com\nWebsite: www.baselmedical.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/96181af0-dfbf-4205-8ef7-e5c3c70fe0e2)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbzpFNJ-20261008","title":"Basel Medical Group Ltd (BMGL) Prices Registered Direct Offering","author":"Globe Newswire","ticker":"BMGL","created":"2026-10-08T17:17:00.099Z","tickers":["BMGL"],"exchange":"NASDAQ","article_body":"Singapore, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq:\nBMGL) (the “Company”) today entered into a placement agency agreement with\nCathay Securities, Inc., as the placement agent (the “Placement Agent”),\nas well as a securities purchase agreement with certain purchasers, pursuant\nto which the Company will issue and sell 6,000,000 units (the “Units”), at\na public offering price of US$1.33 per Unit, each consisting of one ordinary\nshare with no par value (each an “Ordinary Share” and collectively the\n“Ordinary Shares”) or one Pre-Funded Warrant (defined below) of the\nCompany, and one warrant (“Common Warrant”), each to purchase one Ordinary\nShare.\n\nThe Ordinary Shares are listed on the Nasdaq Capital Market under the symbol\n“BMGL”. The Common Warrants and Pre-Funded Warrants will not be listed or\nquoted on any exchange. The total gross proceeds to the Company from the\noffering, before deducting commissions and offering expenses, will be US$7.98\nmillion. The Company estimates that its net proceeds from this offering will\nbe approximately US$7.28 million. The Ordinary Shares issued and to be issued\nupon warrant exercise and pursuant to this offering are registered pursuant to\nthe Company’s effective registration statement on Form F-1 (File No.\n333-298988) (the “Registration Statement”) and will be freely tradeable\nwithout restriction following the closing of this offering.\n\nEach Common Warrant is exercisable immediately on the date of issuance at an\nexercise price per share equal to 110% of the public offering price of each\nUnit sold in this offering and will expire five years from the date of\nissuance. A holder of Common Warrants may, at any time following the closing\nof this offering within the exercise period and in its sole discretion,\nexercise its Common Warrants in whole or in part by means of a zero cash\nexercise price option, in which the holder will receive the number of Ordinary\nShares that would be issuable upon a cash exercise of the Common Warrant,\nwithout payment of additional consideration, or a total of 6,000,000\nadditional Ordinary Shares in the aggregate. As a result, we will likely not\nreceive any additional funds and do not expect to receive any additional funds\nupon the exercise of the Common Warrants. If all of the 6,000,000 Common\nWarrants offered to investors in this offering are exercised on a zero cash\nbasis, an aggregate of 6,000,000 Ordinary Shares would be issued upon such\nzero cash exercise without payment to us of any additional cash.\n\nEach purchaser who purchased Units that would otherwise result in the\npurchaser’s beneficial ownership exceeding 4.99% (or, at the election of the\nholder, such limit may be increased to up to 9.99%) of our outstanding\nOrdinary Shares, were offered the opportunity to purchase Units consisting of\none pre-funded warrant (in lieu of one Ordinary Share, each a “Pre-Funded\nWarrant”) and one Common Warrant. Subject to limited exceptions, a holder of\nPre-Funded Warrants will not have the right to exercise any portion of its\nPre-Funded Warrants if the holder, together with its affiliates, would\nbeneficially own in excess of 4.99% (or, at the election of the holder, such\nlimit may be increased to up to 9.99%) of the number of Ordinary Shares\noutstanding immediately after giving effect to such exercise. Each Pre-Funded\nWarrant will be exercisable for one Ordinary Share. The purchase price of each\nUnit that includes a Pre-Funded Warrant is the final Unit offer price less\nUS$0.01, and the remaining exercise price of each Pre-Funded Warrant will\nequal US$0.01 per share. The Pre-Funded Warrants will be immediately\nexercisable (subject to the beneficial ownership cap) and may be exercised at\nany time until all of the Pre-Funded Warrants are exercised in full.\n\nImmediately prior to this offering, the Company had a total of 1,582,111\nOrdinary Shares issued and outstanding. Immediately upon the completion of the\noffering, the Company will have a total of 7,582,111 Ordinary Shares issued\nand outstanding and a total of 6,000,000 Common Warrants issued and\noutstanding.\n\nThe Company and all of our executive officers, directors and certain\nshareholders beneficially owning 5.0% or more of our ordinary shares prior to\nthis offering have entered into lock-up agreements in connection with the\noffering. Under these agreements, the Company and each of these persons may\nnot, without the prior written approval of the Placement Agent, offer, sell,\ncontract to sell or otherwise dispose of or hedge Ordinary Shares or\nsecurities convertible into or exchangeable for Ordinary Shares, subject to\ncertain exceptions. The restrictions contained in these agreements will be in\neffect for a period of 180 days for the Company and 180 days for the executive\nofficers, directors and such shareholders, after the date of the closing of\nthis offering. The Company has agreed that, for a period of 180 days following\nthe closing date of this offering, it will not, without the prior written\nconsent of the Placement Agent, directly or indirectly issue, offer, sell,\ncontract to sell, grant any option to purchase, or otherwise dispose of any\nOrdinary Shares or any securities convertible into, exercisable for, or\nexchangeable for Ordinary Shares, other than a prospectus filed with the\nCommission pursuant to Rule 424(b) in connection with this offering,\nsupplements or amendments to registration statements or supplements previously\nfiled. The Company has also agreed that, during the same 180 days, it will not\nenter into or consummate any financing or capital-raising transaction,\nincluding any equity line of credit, equity financing, convertible bond,\nconvertible note, other equity-linked financing, or variable rate transaction,\nwithout the prior written consent of the Placement Agent.\n\nCathay Securities, Inc. is acting as exclusive placement agent in connection\nwith this offering. Sichenzia Ross Ference Carmel LLP is acting as counsel to\nthe Company regarding U.S. securities law matters. Hunter Taubman Fischer & Li\nLLC is acting as U.S. securities counsel for the placement agent.\n\nThe securities described above are being offered pursuant to the Registration\nStatement, which was declared effective by the U.S. Securities and Exchange\nCommission (the “SEC”) on September 29, 2026. The offering is being made\nonly by means of a prospectus which is a part of the Registration Statement. A\npreliminary prospectus relating to the offering has been filed with the SEC.\nCopies of the final prospectus relating to the offering, when available, may\nbe obtained from Cathay Securities, Inc., 40 Wall Street, Suite 3600, New\nYork, NY 10005, Attention: Shell Li, or by calling +1 855-939-3888, by email\nrequest to service@cathaysecurities.com.\n\nBefore you invest, you should read the prospectus and other documents the\nCompany has filed or will file with the SEC for more complete information\nabout the Company and the offering. This press release shall not constitute an\noffer to sell, or the solicitation of an offer to buy any of the Company’s\nsecurities, nor shall such securities be offered or sold in the United States\nabsent registration or an applicable exemption from registration, nor shall\nthere be any offer, solicitation or sale of any of the Company’s securities\nin any state or jurisdiction in which such offers, solicitations or sales\nwould be unlawful prior to registration or qualification under the securities\nlaws of such state or jurisdiction. Any offers, solicitations, or offers to\nbuy, or any sales of securities will be made in accordance with the\nregistration requirements of the Securities Act of 1933, as amended.\n\nAbout Basel Medical Group Ltd\n\nBasel Medical is a Singapore-based provider of orthopedic and trauma services,\nsports medicine, orthopedic procedures and surgery, as well as neurosurgical\ntreatments, executive health screening services, occupational medicine,\nrehabilitation, mental and women’s health and general medical practices. Our\noperations are based in Singapore, with our clinics being located at Suntec\nCity Mall, Macpherson Road, Toa Payoh, Margaret Drive, Tampines, Gateway East\nand Gleneagles Medical Centre. Over the last 20 years, our group has forged\nstrong and lasting relationships with a wide corporation clientele,\nparticularly those in the construction, marine and oil & gas industries, which\nunderpin our robust business model. As an medical service provider in\nSingapore with a track record of over 20 years, we are well-positioned to ride\nthe wave of growth opportunities in the private healthcare industry in\nSingapore and across Southeast Asia driven by ageing populations, rising\nincome levels, increasing private insurance coverage, increasing expenditure\non healthcare, growing sports participation rate and Singapore’s position as\na premium destination for healthcare services in Asia. Our management and\nmedical practitioner team comprises a roster of orthopedic and neurosurgery\nspecialists, general practitioners, corporate finance and healthcare\npartnership specialists. Basel Medical Group Ltd serves as the holding company\nof our group and we conduct our operations through our operating subsidiaries\nbased in Singapore. For more information, please visit the Company’s\nwebsite: www.baselmedical.com.\n\nForward-Looking Statements\n\nCertain statements in this announcement are forward-looking statements, which\ninvolve known and unknown risks and uncertainties and are based on the\nCompany’s current expectations and projections about future events that may\naffect its financial condition, results of operations, business strategy and\nfinancial needs. Investors can find many (but not all) of these statements by\nthe use of words such as “aim”, “anticipate”, “believe”,\n“estimate”, “expect”, “going forward”, “intend”, “may”,\n“plan”, “potential”, “predict”, “propose”, “seek”,\n“should”, “will”, “would” or other similar expressions in this\npress release. The Company undertakes no obligation to update or revise\npublicly any forward-looking statements to reflect subsequent occurring events\nor circumstances, or changes in its expectations, except as may be required by\nlaw. Although the Company believes that the expectations expressed in these\nforward-looking statements are reasonable, it cannot assure you that such\nexpectations will turn out to be correct, and the Company cautions investors\nthat actual results may differ materially from the anticipated results and\nencourages investors to review other factors that may affect its future\nresults in the Company’s filings with the SEC.\n\nMedia Contact:\n\nBasel Medical Group Ltd\nPhone: +65 6291 9188\nE-mail: contact@baselmedical.com\nWebsite: www.baselmedical.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/96181af0-dfbf-4205-8ef7-e5c3c70fe0e2)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-08T17:17:00.137883798Z","server_sent_at_ms":1791479820137},"received_at":"2026-10-08T17:17:00.190Z","source_url":null},"analysis":{"id":"153095","press_release_id":"164685","analysis_json":{"industry":{"label":"Health Care Providers & Services","sector":"Health Care"},"redFlags":["offering increases share count from ~1.58M to ~7.58M — roughly 380% dilution","zero-cash exercise warrants add up to 6,000,000 more shares with no proceeds","company explicitly does not expect additional funds from warrant exercises","net proceeds ~91.5% of gross with unspecified use of proceeds","tiny float relative to offering size raises overhang and volatility risk"],"eventType":"offering","narrative":"Basel Medical Group priced a registered direct offering of 6,000,000 units at US$1.33 per unit, raising US$7.98 million gross (about US$7.28 million net) with Cathay Securities as exclusive placement agent.\n\nThe dilution is extreme: the offering takes shares outstanding from 1,582,111 to 7,582,111, and each Common Warrant includes a zero-cash exercise option that can add another 6,000,000 shares with no additional proceeds to the company.\n\nCompany insiders and 5%+ holders signed 180-day lock-ups, and the company agreed not to pursue any additional financing for 180 days without placement agent consent.\n\nThe raise is heavily dilutive and warrant zero-cash mechanics signal investors paid essentially for stock, not for future exercise proceeds.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Micro-cap raises $8M while quintupling its share count — massive dilution with no-exercise-proceeds warrants."},"keyFigures":{"dealValueUsd":"$7.98 million","offeringPrice":1.33,"sharesOffered":6000000,"customDimensions":{"lockup_days":180,"net_proceeds":"$7.28 million","warrant_term":"five years","gross_proceeds":"$7.98 million","warrant_exercise_premium":"110%","warrant_shares_zero_cash":6000000,"shares_outstanding_pre_offering":1582111,"shares_outstanding_post_offering":7582111}},"namedEntities":{"people":[{"name":"Shell Li","role":"placement agent contact, Cathay Securities"}],"products":["Common Warrants","Pre-Funded Warrants"],"companies":[{"name":"Basel Medical Group Ltd","ticker":"BMGL","relationship":"issuer"},{"name":"Cathay Securities, Inc.","relationship":"placement agent"},{"name":"Sichenzia Ross Ference Carmel LLP","relationship":"issuer counsel"},{"name":"Hunter Taubman Fischer & Li LLC","relationship":"placement agent counsel"}],"dollarAmounts":[{"amount":"US$1.33","context":"public offering price per Unit"},{"amount":"US$7.98 million","context":"gross proceeds before commissions and expenses"},{"amount":"US$7.28 million","context":"estimated net proceeds"},{"amount":"US$0.01","context":"Pre-Funded Warrant exercise price"}]},"materialImpact":{"score":5,"reasoning":"Registered direct offering of 6,000,000 units against only 1,582,111 shares outstanding — dilution far exceeds 20%, and attached Common Warrants carry a zero-cash exercise option adding another 6,000,000 shares with no proceeds to the company."},"tickerRelevance":{"others":[],"primary":"BMGL"},"globalImportance":18,"audienceRelevance":15,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"heavy-dilution-offering","dilutionMagnitude":"~380% share count increase","retailFavoriteBoost":false}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"bearish","material_impact_score":5,"narrative":"Basel Medical Group priced a registered direct offering of 6,000,000 units at US$1.33 per unit, raising US$7.98 million gross (about US$7.28 million net) with Cathay Securities as exclusive placement agent.\n\nThe dilution is extreme: the offering takes shares outstanding from 1,582,111 to 7,582,111, and each Common Warrant includes a zero-cash exercise option that can add another 6,000,000 shares with no additional proceeds to the company.\n\nCompany insiders and 5%+ holders signed 180-day lock-ups, and the company agreed not to pursue any additional financing for 180 days without placement agent consent.\n\nThe raise is heavily dilutive and warrant zero-cash mechanics signal investors paid essentially for stock, not for future exercise proceeds.","key_figures":{"dealValueUsd":"$7.98 million","offeringPrice":1.33,"sharesOffered":6000000,"customDimensions":{"lockup_days":180,"net_proceeds":"$7.28 million","warrant_term":"five years","gross_proceeds":"$7.98 million","warrant_exercise_premium":"110%","warrant_shares_zero_cash":6000000,"shares_outstanding_pre_offering":1582111,"shares_outstanding_post_offering":7582111}},"named_entities":{"people":[{"name":"Shell Li","role":"placement agent contact, Cathay Securities"}],"products":["Common Warrants","Pre-Funded Warrants"],"companies":[{"name":"Basel Medical Group Ltd","ticker":"BMGL","relationship":"issuer"},{"name":"Cathay Securities, Inc.","relationship":"placement agent"},{"name":"Sichenzia Ross Ference Carmel LLP","relationship":"issuer counsel"},{"name":"Hunter Taubman Fischer & Li LLC","relationship":"placement agent counsel"}],"dollarAmounts":[{"amount":"US$1.33","context":"public offering price per Unit"},{"amount":"US$7.98 million","context":"gross proceeds before commissions and expenses"},{"amount":"US$7.28 million","context":"estimated net proceeds"},{"amount":"US$0.01","context":"Pre-Funded Warrant exercise price"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-08T17:17:08.211Z","global_importance":18,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"heavy-dilution-offering","dilutionMagnitude":"~380% share count increase","retailFavoriteBoost":false}},"durationMs":8078,"modelName":"glm-5.3-flashx"}}